La vendita allo scoperto per OptiNose dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di OptiNose. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

OptiNose (NASDAQ:OPTN) Azioni, Report sulle vendite allo scoperto

OptiNose

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

OptiNose Inc

Friday,&nbsp;Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported first-quarter 2025 adjusted EPS of $1.88, up 9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.62</a>.
Sales decreased 4% to $52.28 billion, beating the&nbsp;consensus of $50.90 billion. Adjusted operating earnings increased 12% to&nbsp;$625 million.
First-quarter revenue for the Pharmaceutical and Specialty Solutions segment decreased by 5% to&nbsp;$48.0 billion. Excluding the customer contract expiration, revenue increased by 16%, driven by brand and specialty pharmaceutical sales growth <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41679244/cardinal-health-reports-first-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook" rel="noreferrer noopener">from existing customers</a>.
Pharmaceutical and Specialty Solutions segment profit increased 16% to&nbsp;$530 million, driven by a higher contribution from brand and specialty products, including the earlier seasonal launch of COVID-19 vaccine distribution and positive generics program performance.
The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty drugs, and OTC products and offers services for specialty pharmaceuticals, supporting both manufacturers and healthcare providers and pharmacy management services.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40694838/opioid-settlement-drug-distributors-mckesson-cencora-cardinal-health-to-pay-300m-to-health-insurer" rel="noreferrer noopener">Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers</a>
Revenue for the Global Medical Products and Distribution segment increased 3% to&nbsp;$3.1 billion, driven by volume growth from existing customers.
Global Medical Products and Distribution (GMPD) segment profit decreased to&nbsp;$8 million, primarily due to higher manufacturing and health and welfare costs, largely offset by improved net inflationary impacts, including mitigation initiatives and growth from existing customers.
GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as distributes medical, surgical and laboratory products known as national brand products
&#8220;We began fiscal 2025 by delivering strong operational and financial performance, led by the Pharmaceutical and Specialty Solutions segment,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
&#8220;The strength and resiliency of our largest and most significant business continues to shine, giving us confidence to raise our fiscal 2025 enterprise guidance only a quarter into the year,&#8221; Hollar added.
Outlook:&nbsp;Cardinal Health has raised its fiscal year 2025 outlook for adjusted EPS to $7.75-$7.90 from <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b" rel="noreferrer noopener">prior guidance of</a> $7.55-$7.70 versus consensus of $7.63.
The guidance includes an update to the company&#8217;s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth.
The company also updated its Global Medical Products and Distribution segment profit outlook to&nbsp;$140 million&nbsp;to&nbsp;$175 million, from approximately&nbsp;$175 million, primarily due to the impact of higher health and welfare costs.
Additionally, the company updated expectations for its adjusted free cash flow to&nbsp;$1.0 billion&nbsp;to&nbsp;$1.5 billion, from approximately&nbsp;$1.0 billion.
Price Action: CAH stock is trading 2.97% higher at $111.74 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41661764/ford-to-halt-f-150-ev-production-for-7-weeks-next-month" target="_blank" rel="noreferrer noopener">Ford To Halt F-150 EV Production For 7 Weeks Next Month</a></li>
</ul>
Photo via Company

Earnings

Large Cap

News

Guidance

Health Care

Movers

General

Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Market Outperform and raises the price target from $497 to $606.

Price Target

Analyst Ratings

ARGX

JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $606

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41679046/exxonmobil-announces-third-quarter-2024-results" rel="noreferrer noopener">third-quarter&nbsp;results</a>.&nbsp;
Total revenues and other income&nbsp;stood at&nbsp;$90.016 billion, missing the consensus of&nbsp;$93.938 billion.
Net production stood at 4,582 thousand oil-equivalent barrels per&nbsp;day, an increase of&nbsp;5%&nbsp;from the previous quarter, driven by increased volumes from Pioneer assets.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41659147/exxon-mobil-q3-preview-will-rising-production-cost-cuts-boost-earnings" rel="noreferrer noopener">Exxon Mobil Q3 Preview: Will Rising Production, Cost Cuts Boost Earnings?</a>
Adjusted net profit came in at&nbsp;$8.61 billion, down from&nbsp;$9.24 billion in the prior quarter. Adjusted EPS stood at&nbsp;$1.92,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.88</a>.
Exxon&#8217;s&nbsp;capital and exploration expenditures stood at&nbsp;$7.16 billion in the&nbsp;third quarter, bringing year-to-date 2024 expenditures to&nbsp;$20 billion, in line with the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">company&#8217;s full-year&nbsp;guidance&nbsp;of&nbsp;$28 billion.</a>
This month, ExxonMobil and HELLEniQ ENERGY completed Phase 1 of offshore Crete exploration,<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41270873/exxonmobil-helleniq-energy-jv-completes-first-exploration-phase-in-crete-eyes-next-steps" rel="noreferrer noopener"> gathering 7,789 km of seismic data</a>.
Cost Reduction: The company achieved a cumulative structural cost savings of&nbsp;$11.3&nbsp; billion versus 2019, including an additional&nbsp;$1.6 billion&nbsp;of savings during the year and&nbsp;$0.6 billion&nbsp;during the quarter.
The company plans to deliver cumulative savings totaling&nbsp;$15 billion&nbsp;through the end of 2027 versus 2019.
Dividend Boost: Exxon raised its dividend per share by 4% to $0.99 from&nbsp;$0.95 per share, payable on December 10, to shareholders of record as of November 14.
The company&#8217;s year-to-date shareholder distributions totaled $26.1 billion, comprising $12.3 billion in dividends and $13.8 billion in share repurchases.
Darren Woods, chairman and chief executive officer, said, &#8220;Our industry-leading results continue to demonstrate how our enterprise-wide transformation is improving the structural earnings power of the company.&#8221;
&#8220;In the Upstream, we&#8217;ve doubled the profitability of the barrels we produce on a constant price basis. In Product Solutions, we&#8217;ve high-graded our refining footprint and increased high-value product sales.&#8221;
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;SPDR Select Sector Fund – Energy Select Sector&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: XOM shares are up 2.07% at $119.20 premarket at the last check Friday.
Photo: Del Henderson Jr. via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41553999/exxon-mobils-golden-pass-lng-plant-gets-3-year-extension-amid-contractor-challenges-report" target="_blank" rel="noreferrer noopener">Exxon Mobil&#8217;s Golden Pass LNG Plant Gets 3-Year Extension Amid Contractor Challenges: Report</a></li>
</ul>

Equities

DRLL

Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More

Piper Sandler analyst Crispin Love maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Overweight and raises the price target from $23 to $25.

Piper Sandler Maintains Overweight on Blue Owl Cap, Raises Price Target to $25

JMP Securities analyst Nicholas Jones maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and raises the price target from $265 to $285.

AMZN

JMP Securities Maintains Market Outperform on Amazon.com, Raises Price Target to $285

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1242 to $1195.

REGN

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) — the parent company of KFC, Pizza Hut, and Taco Bell — will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/YUMC/earnings">opening bell on Monday, Nov. 4.</a>
Analysts expect the China-based company to report quarterly earnings at 67 cents per share, up from 59 cents per share in the year-ago period. Yum China projects to report revenue of $3.05 billion for the recent quarter, compared to $2.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 5, Yum China reported second-quarter results yesterday. Revenue increased 1% year over year to $2.68 billion, missing the consensus of $2.77 billion.
With the recent buzz around Yum China, some investors may be eyeing potential gains from the company's dividends too. As of now, Yum China offers an annual dividend yield of 1.45%, which is a quarterly dividend amount of 16 cents per share (64 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $413,531 or around 9,375 shares. For a more modest $100 per month or $1,200 per year, you would need $82,706 or around 1,875 shares.
To Calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend (64 cents in this case). So, $6,000 / $0.64 = 9,375 ($500 per month), and $1,200 / $0.64 = 1,875 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How That Works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of Yum China fell 1.3% to close at $44.11 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Unsplash

Long Ideas

Markets

Trading Ideas

YUMC

How To Earn $500 A Month From Yum China Stock Ahead Of Q3 Earnings

Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) reported quarterly earnings of C$2.33 per share which beat the analyst consensus estimate of C$2.00 by 16.5 percent. This is a 15.58 percent decrease over earnings of C$2.76 per share from the same period last year. The company reported quarterly sales of C$13.259 billion which missed the analyst consensus estimate of C$15.636 billion by 15.20 percent. This is a 4.75 percent decrease over sales of C$13.920 billion the same period last year.

Earnings Beats

Earnings Misses

Imperial Oil Q3 2024 GAAP EPS C$2.33 Beats C$2.00 Estimate, Sales C$13.259B Miss C$15.636B Estimate

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and lowers the price target from $130 to $81.

DA Davidson Maintains Buy on Estee Lauder Cos, Lowers Price Target to $81

2024 Guidance The Company currently estimates net income to be within a range of $7.18 to $7.28 per diluted share and FFO to be within a range of $12.80 to $12.90 per diluted share, excluding the $0.14 per diluted share of unrealized losses in fair value adjustments of the Klépierre exchangeable bonds and publicly traded equity instruments, net for the year ending December 31, 2024.&nbsp; &nbsp;&nbsp;
The following table provides the GAAP to non-GAAP reconciliation for the expected range of estimated net income attributable to common stockholders per diluted share to FFO per diluted share:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">For the year ending December 31, 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Estimated net income attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.18</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.28</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization including Simon's share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of unconsolidated entities</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gain on acquisition of controlling interest, sale or</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">disposal of, or recovery on, assets and interest in</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">unconsolidated entities and impairment, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.66</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.76</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Unrealized losses in fair value adjustments</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of the Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share, excluding unrealized</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">losses in fair value adjustments of the</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.80</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.90</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Simon Property Group Sees FY24 EPS $7.18-$7.28 Vs $7.12 Est.; FFO $12.80-$12.90

Piper Sandler analyst Thomas Champion maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Overweight and raises the price target from $54 to $65.

RBLX

Piper Sandler Maintains Overweight on Roblox, Raises Price Target to $65

TOVX: 67% &#x7C; <a href="https://www.benzinga.com//node/41665409">Theriva Biologics shares are trading higher after the company announced it was selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.</a>
&nbsp;
TEAM: 21% &#x7C; <a href="https://www.benzinga.com//node/41680189">Atlassian shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 revenue guidance above estimates.</a>
&nbsp;
EOSE: 14% &#x7C; <a href="https://www.benzinga.com//node/41680096">Eos Energy Enterprises shares are trading higher after the company announced it achieved its second set of performance milestones where achieving these results enables an additional $65 million from the delayed draw term loan.</a>

EOSE

TEAM

TOVX

Market-Moving News for November 1st

U.S.-listed Chinese EV startups Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) reported their October delivery numbers on Friday with Li Auto topping the three by a significant margin.
Li Auto Tops The Chart: Li Auto said on Friday that it delivered 51,443 vehicles in October, marking a 27.3% jump in sales year-over-year but a 4% drop from September when it delivered nearly 54,000 vehicles.
The rise in sales, <a href="https://www.benzinga.com/news/earnings/24/10/41647868/li-auto-q3-earnings-24-topline-growth-1-million-deliveries-milestone-q4-revenue-outlook-lags-street">Li Auto said</a>, could be attributed to robust sales across its model lineup. The company also crossed the landmark of delivering over 1 million vehicles cumulatively in October. 
XPeng Mona M03 Deliveries Exceed 10k Units: XPeng&nbsp;also witnessed its deliveries rise in October but couldn't keep up with Li Auto's pace. The company delivered 23,917 vehicles last month, marking an increase of 20% year-over-year and 12% from September.
The Guangzhou-based EV startup said that the company&#8217;s deliveries of the <a href="https://www.benzinga.com/markets/equities/24/07/39618570/xpeng-debuts-mona-series-with-m03-with-official-launch-in-august-report">XPENG MONA M03 </a>hatchback coupe alone exceeded 10,000 units. 
ONVO Spurs Nio Forward: Shanghai-based Nio, meanwhile, delivered 20,976 vehicles in October, including 16,657 NIO brand vehicles and 4,319 <a href="https://www.benzinga.com/markets/equities/24/10/41195060/tesla-rival-nio-accelerates-global-expansion-to-launch-evs-in-middle-east-amid-eu-tariff-concern">ONVO brand vehicles</a>. This marks a near 1% dip from its September delivery numbers and a whopping 30.5% rise from its sales in October 2023.
Deliveries of the first ONVO vehicle &#8211; the ONVO L60 &#8211; commenced in late September, making October the first whole month of sales for the family-oriented EV brand.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">Chinese EV Behemoth BYD Tops Tesla's Revenue For First Time Since 2022 In Q3</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

XPEV

Li Auto Leads The Pack, XPeng, Nio Clock Growth: Here's How October Deliveries Of Chinese EV Startups Stack Up

HSBC analyst Meredith Jensen downgrades Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) from Buy to Hold and announces $156 price target.

Downgrades

HSBC Downgrades Hyatt Hotels to Hold, Announces $156 Price Target

Michael Saylor&#8216;s declaration that &#8220;MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the public equity play on Bitcoin maximalism&#8221; aptly defines the company&#8217;s pioneering approach in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41585530/asias-microstrategy-metaplanet-buys-another-10-4m-in-bitcoin-exceeds-1-000-btc-holdings">corporate Bitcoin holdings</a>.
Saylor highlighted the company&#8217;s strategy in a post on X on Thursday:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy is the public equity play on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Maximalism. <a href="https://t.co/96lpcdN5Zi">pic.twitter.com/96lpcdN5Zi</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1852116357724475532?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
How MicroStrategy Leverages Bitcoin: MicroStrategy has not only redefined its own treasury strategy but also set a model that other companies are now beginning to emulate.
The firm's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-centric approach, producing returns well above the S&amp;P 500, has led to notable shifts in corporate treasury strategies worldwide.
Since MicroStrategy's pivot in 2020, the company has consistently purchased Bitcoin, achieving an annual average return of 44%, significantly higher than the S&amp;P 500&#8217;s 12% <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">during the same period</a>, Saylor told CNBC in a recent interview.
Notably, MicroStrategy's strategy yielded an 825% return, outperforming even Nvidia&#8217;s 821% rise, further showcasing the power of its Bitcoin holdings. 
The firm continues its role as a &#8220;cash cow&#8221; in the software sector while embracing Bitcoin as a primary treasury asset, according to Saylor. 
This dual model allows MicroStrategy to finance Bitcoin acquisitions through securitized instruments like convertible bonds, presenting investors with exposure to Bitcoin at a reduced volatility level.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41667204/what-coin-should-i-buy-binance-founder-changpeng-zhao-shares-anecdotes-from-4-month-prison">&#8216;What Coin Should I Buy?&#8217;—Binance Founder Changpeng Zhao Shares Anecdotes From 4-Month Prison Stint</a>
Who&#8217;s Following The MicroStrategy Apporach: The bold move has stirred interest among other companies, especially as MicroStrategy recently announced its acquisition of 25,889 BTC in Q3, valued at $1.6 billion.
The strategy brought the company's total holdings to 252,220 BTC, worth approximately $18.23 billion, positioning it as a prominent advocate for using Bitcoin as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">hedge in uncertain economic times.</a> 
Despite the risks associated with Bitcoin's volatility, Saylor emphasized that Bitcoin "fixes the balance sheet," offering liquidity and resilience to a firm's finances. 
MicroStrategy plans to raise an additional $42 billion through equity and debt financing in the coming years to further its Bitcoin acquisitions, reinforcing its belief in Bitcoin's long-term value.
Following MicroStrategy's example, companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) have implemented similar Bitcoin-centered approaches.
Cathedra Bitcoin, listed on the TSX Venture Exchange, has transitioned its operations from mining to data management to sustainably increase its Bitcoin holdings. 
Meanwhile, Metaplanet has prioritized Bitcoin growth month-over-month, achieving a 587% stock increase this year, reflecting a shift toward maximizing Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942247/microstrategys-bitcoin-playbook-is-becoming-a-hit-among-companies-but-theres-a-catch">reserves to enhance shareholder value.</a>
This shift, coined the &#8220;<a href="https://www.benzinga.com/startups/24/10/41434521/tesla-quietly-transfers-765-million-in-bitcoin-putting-musks-cryptocurrency-strategy-under-intense-s">maximize Bitcoin per share</a>&#8221; approach, is becoming a compelling alternative for firms seeking inflation hedges and asset stability.
For those interested in the ongoing impact of this strategy on the digital finance landscape, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a pivotal platform to explore further, with discussions on corporate adoption and innovations in digital assets expected.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">Donald Trump Wishes Bitcoiners &#8216;Happy Birthday&#8217;, Vows To &#8216;End Kamala&#8217;s War On Crypto&#8217; As World Liberty Financial Falls Way Short Of Fundraising Goal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CBTTF

MSTR

SMLR

Michael Saylor Calls MicroStrategy The 'Public Equity Play On Bitcoin Maximalism': Here's Who's Following This Approach

Dividends
Today, Simon&#39;s Board of Directors declared a quarterly common stock dividend of $2.10 for the fourth quarter of 2024. &nbsp;This is an increase of $0.20, or 10.5% year-over-year.&nbsp; The dividend will be payable on December 30, 2024 to shareholders of record on December 9, 2024.&nbsp;
Simon&#39;s Board of Directors declared the quarterly dividend on its 8 3/8% Series J Cumulative Redeemable Preferred Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGPRJ#NYSE">SPGPRJ</a>) of $1.046875 per share, payable on December 30, 2024 to shareholders of record on December 16, 2024.&nbsp;

Dividends

SPGPRJ

Simon Property Group Increases Quarterly Dividend From $2.05 To $2.10 Per Share

Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. This is a 21.82 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $88.81 million which beat the analyst consensus estimate of $83.92 million by 5.82 percent. This is a 17.23 percent decrease over sales of $107.29 million the same period last year.

Arbor Realty Trust Q3 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $88.81M Beat $83.92M Estimate

Brings Extensive Deal-Making And Strategic Experience, Including $700M Licensing Deal With Dr. Reddy's Lab; Highlights Potential Benefits Of Low-Dose Interleukin-2 In Alzheimer's Phase 2 Trial

Management

COYA

Coya Therapeutics Appoints Arun Swaminathan, Ph.D., As CEO

Contracts

CLSK

Canaan To Provide CleanSpark With 3800 Avalon A1566I Immersion Cooling Miners; Financial Details Not Disclosed

Biotech

Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029

Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose (OPTN – Research Report) today. The company's shares closed yesterday at $1.0...

Lake Street Sticks to Its Buy Rating for Optinose (OPTN)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The stock market rally has been showing no sign of stopping, and while most of it has been driven by Big Tech, it is worth looking into some little-known <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. These stocks usually see huge breakouts and trade at big premiums during bullish rallies. We haven&rsquo;t seen that happen across most penny stocks just yet, but I think it&rsquo;s a good reason to buy up some high-potential names if you are willing to stomach the risks.



Of course, many of these penny stocks are more than just short- to mid-term plays. Most of these up-and-coming firms have huge growth runways, and analysts expect explosive growth over the next decade. If they execute as expected, I believe it is possible that they could turn a $10k investment into something life-changing. Let&rsquo;s take a look!



<h2>OptiNose (OPTN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>OptiNose (NASDAQ:<a href="https://investorplace.com/stock-quotes/optn-stock-quote/">OPTN</a>) is a specialty pharmaceutical company focused on developing products for patients with diseases treated by otolaryngologists and allergists. I&rsquo;ve been closely watching this little-known penny stock, and I believe it could be a potential hidden gem for risk-tolerant investors.



Their lead product, XHANCE, has shown strong efficacy in treating chronic sinusitis, which, according to their market research, is a key driver of prescribing behavior.



OptiNose is admittedly a speculative bet, but I think the potential payoff could be substantial. The stock has been stuck trading around the $1 level for over a year, but with these promising developments, I wouldn&rsquo;t be surprised to see a breakout if they can execute well.



What I particularly like about OptiNose is its solid and rapidly growing sales base. Analysts are projecting revenue to skyrocket from <a href="https://seekingalpha.com/symbol/OPTN/earnings/estimates" target="_blank">$92 million in 2024 to $342 million by 2028</a>, with profitability expected by 2026.



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-9.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-9.png" alt="penny stocks: OptiNose operating profits"> Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div>If everything goes according to plan, the stock is trading at just 3 times 2027 earnings estimates right now.



Of course, the key question is whether their growth plans will play out as hoped. Biotech and pharma startups are always a risky bet. But OptiNose seems to have weathered the worst and has a strong foundation upon which to build. This beaten-down stock could be a hidden multibagger in the making. Just be sure to do your own diligence.



<h2>Unusual Machines (UMAC)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2019/04/dronesmsn-300x165.jpg" alt=""><div>Source: Shutterstock</div></div>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) manufactures drones and drone components. I&rsquo;m very bullish on drone startups like Unusual Machines. There simply aren&rsquo;t enough of these companies in the U.S. right now, especially ones focused on producing inexpensive military drones for reconnaissance and combat purposes.



Most of those cheaper military drones are currently mass-produced in China and Russia. Meanwhile, the U.S. relies on a handful of giant defense contractors making very expensive drones. I believe this supply chain vulnerability is becoming increasingly apparent to governments worldwide. They&rsquo;re scrambling to ink deals with promising upstart drone makers to diversify their sources.



That&rsquo;s where Unusual Machines comes in. Sure, with just <a target="_blank" href="https://www.stocktitan.net/news/UMAC/">$619,000 in sales</a> (the sales were made in just 45 days) last quarter, it&rsquo;s tiny and unprofitable. However, after a recent $5 million IPO and acquiring key operating units like Fat Shark and Rotor Riot, this Red Cat Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/rcat-stock-quote/">RCAT</a>) spinoff has big potential, in my view. Management is moving fast to start churning out NDAA-compliant drone parts from its new Orlando headquarters.



If it can secure those critical &ldquo;Blue UAS&rdquo; certifications soon, lucrative government contracts could follow and really jumpstart growth. Of course, this is an extremely speculative play. I&rsquo;m banking on a rosy future that may not materialize. UMAC is only suitable if you seriously want to turn $10k into a million and take on the risks that come with it.



<h2>High Tide (HITI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div>High Tide (NASDAQ:<a href="https://investorplace.com/stock-quotes/hiti-stock-quote/">HITI</a>) operates as a retail-focused cannabis company. I covered this little-known penny stock over a year ago, and it&rsquo;s already up by a whopping 80% since then, but I believe High Tide still has substantial upside potential. High Tide generated <a target="_blank" href="https://www.tipranks.com/news/company-announcements/high-tide-achieves-record-q2-financial-milestones">9.4 million CAD in free cash flow in Q2</a>, more than the prior two quarters combined. It&rsquo;s a rare gem in the cannabis space that isn&rsquo;t burning cash and is on the cusp of sustained profitability.



Once High Tide firmly establishes consistent earnings and accelerates its expansion, I expect this stock could deliver multibagger returns from current levels based solely on the Canadian market opportunity. However, the real game-changer would be U.S. federal cannabis legalization. High Tide already has a footprint in the U.S. but operates with restraints.



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-10.png"><img width="1226" height="741" src="https://investorplace.com/wp-content/uploads/2024/07/chart-10.png" alt="High Tide sales by region chart"> Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div>If it can replicate its Canadian success in a market 10 times larger, this under-the-radar stock could turn a $10k investment into something much more meaningful.



<h2>Blackline Safety (BLKLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/fr_firstindustrial1600-300x169.png" alt="Back View of the Head of the Project Holds Laptop and Discussing Product Details with Chief Engineer while They Walk Through Modern Factory., FR rents out these spaces in the U.S."><div>Source: Gorodenkoff / Shutterstock.com</div></div>Blackline Safety (OTCMKTS:<a href="https://investorplace.com/stock-quotes/blklf-stock-quote/">BLKLF</a>) is a Canadian industrial safety company that is riding the wave of onshoring and industrialization. Shares have already surged 150% from their late-2022 trough, but I think there&rsquo;s plenty of room for this rebound to run. The stock still trades nearly 40% below its February 2020 peak despite the company being perfectly positioned to capitalize on the manufacturing renaissance in the U.S. and Canada.



As companies bring production closer to home, they must ensure their facilities meet the rigorous safety standards in these markets. That&rsquo;s where Blackline shines. Its connected safety technology is already seeing booming demand, with <a target="_blank" href="https://www.morningstar.com/news/business-wire/20240613677452/blackline-safety-reports-highest-quarterly-revenue-ever-q2-hits-316m-up-31-year-over-year">revenue jumping 31% YOY to a record $31.6 million</a> in Q2.



Blackline achieved this growth while also expanding its gross margins to 57% and slashing its cash burn by 78%. This tells me that as the company scales up to meet the surging need for industrial safety, its bottom line could boom.



So, while Blackline may be under the radar now, I believe it&rsquo;s a hidden gem that won&rsquo;t stay hidden for long.



<h2>Talkspace (TALK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/talkspace-300x169.jpg" alt="The Talkspace (TALK) logo is displayed on a smartphone screen."><div>Source: Ben__Stevens / Shutterstock.com</div></div>Talkspace (NASDAQ:<a href="https://investorplace.com/stock-quotes/talk-stock-quote/">TALK</a>) is a leading virtual behavioral health company that connects individuals with licensed therapists through its platform. While telemedicine stocks were all the rage during the COVID-19 pandemic, Talkspace&rsquo;s shares have been on a wild ride since going public. After a sharp decline, the stock surged nearly 500% from Q1 2023 to Q1 2024 before recently pulling back around 43%. I believe this presents an attractive entry point.



In Q1 2024, Talkspace delivered <a target="_blank" href="https://www.investing.com/news/stock-market-news/earnings-call-talkspace-reports-profitability-in-q1-with-revenue-growth-93CH-3427451">36% YOY revenue growth to $45.4 million</a> and achieved its first quarter of profitability with an $800,000 adjusted EBITDA. Management&rsquo;s execution on expanding covered lives, and driving utilization is clearly paying off. The recent Medicare launch in multiple states offers another significant growth catalyst.



With profits expected in 2025, along with a <a target="_blank" href="https://seekingalpha.com/symbol/TALK/earnings/estimates">projected 26% sales growth</a> in 2024 and 17-20% annual increases thereafter, I see ample room for upside. Talkspace is well-positioned to benefit from powerful tailwinds. This includes the destigmatization of mental health and younger generations preferring to do everything online.



<h2>Kneat.com (KSIOF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>Kneat.com (OTCMKTS:<a href="https://investorplace.com/stock-quotes/ksiof-stock-quote/">KSIOF</a>) provides software validation solutions for the life sciences industry. The stock has rebounded significantly, up 37% in the past six months alone. I believe Kneat is well-positioned to benefit from the plethora of biotech startups that need validation software to ensure compliance with industry regulations.



In Q1, Kneat&rsquo;s annual recurring revenue <a target="_blank" href="https://financialpost.com/globe-newswire/kneat-announces-record-revenue-for-first-quarter-2024">jumped an impressive 57% to 42.1 million CAD</a>. The gross profit margin expanded from 67% to a robust 74%, while operating expenses grew at a much more modest 17% pace compared to the 77% surge in Q1 2023.



Management noted they are landing major new customer wins across North America, Europe, and Asia, which are fueling the growth. However, the real potential lies in expanding these relationships over time. As Kneat becomes ingrained and trusted within organizations, it can multiply its revenue per customer.



GuruFocus&rsquo; DCF model believes the stock will compound through 2026.



<div><a href="https://investorplace.com/wp-content/uploads/2024/07/chart-11.png"><img width="1200" height="628" src="https://investorplace.com/wp-content/uploads/2024/07/chart-11.png" alt="KSIOF gurufocus price"> Click to Enlarge</a><div>Source: Chart courtesy of <a href="https://GuruFocus.com">GuruFocus.com</a></div></div><h2>One Stop Systems (OSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/computers1600d-300x169.jpg" alt="a man working on a computer hard drive"><div>Source: Shutterstock</div></div>One Stop Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/oss-stock-quote/">OSS</a>) designs and manufactures high-performance edge computing systems for AI and other applications. Despite seeing a <a target="_blank" href="https://www.marketbeat.com/stocks/NASDAQ/OSS/earnings/">24.6% YOY revenue decline to $12.65 million</a> in Q1 2024, I believe OSS is poised for a strong rebound as AI takes off.



The company has done a stellar job shifting its focus to the booming defense and commercial markets, especially for AI and machine learning at the edge. CEO Mike Knowles <a target="_blank" href="https://markets.businessinsider.com/news/stocks/one-stop-systems-oss-strong-buy-rating-on-ai-pivot-and-long-term-growth-potential-1033188679">noted</a> OSS has expanded its 5-year pipeline to over $1 billion, with 70% from multi-year platform opportunities that should drive more predictable revenue.



While the near-term upside may be limited as many AI/ML applications are still in development and testing phases, I&rsquo;m confident OSS is very well-positioned for the coming wave. HPC and enterprise computing needs are exploding as AI startups proliferate, and transformative systems like OpenAI&rsquo;s Sora could send demand soaring even higher.



OSS is admittedly a high-risk, high-reward bet in this nascent industry. But for investors willing to stomach the volatility, I believe getting in early on OSS&rsquo;s turnaround story could deliver incredible returns if the AI rally keeps charging ahead in the years to come.



On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;
<div>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/7-little-known-penny-stocks-that-can-turn-10k-into-1-million/">7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Little-Known Penny Stocks That Can Turn $10K Into $1 Million

OptiNose GAAP EPS of -$0.05 beats by $0.03, revenue of $20.49M misses by $0.59M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OptiNose (NASDAQ:<a href="https://investorplace.com/stock-quotes/optn-stock-quote/">OPTN</a>) just reported results for the second quarter of 2024.<ul><li>OptiNose reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -8 cents.</li><li>The company reported revenue of $20.49 million.</li><li>This was 0.44% worse than the analyst estimate for revenue of $20.58 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/optn-stock-earnings-optinose-for-q2-of-2024/">OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OPTN Stock Earnings: OptiNose Beats EPS, Misses Revenue for Q2 2024

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Optinose (OPTN – Research Report), with a price target...

Optinose's XHANCE Poised for Market Expansion and Growth: A Buy Rating Review

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Optinose ( ($OPTN) ) has issued an announcement. Catherine Owen has stepped down from the Board of Directors at OptiNose, Inc., leaving amicably wi...

Catherine Owen Departs Optinose Board for CEO Role at Acadia

Optinose names Terry Kohler as CFO

Optinose ( ($OPTN) ) has shared an announcement. OptiNose, Inc. has appointed Terry Kohler, a seasoned biotech finance expert with over two decades...

OptiNose Names Terry Kohler New CFO with Incentive Grant

Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose (OPTN – Research Report) today. The company's shares closed yesterday at $0.7...

Comments

OptiNose

Vendite allo scoperto

OptiNose (NASDAQ:OPTN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO